(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 April 2011 (14.04.2011)

PCT

(10) International Publication Number
WO 2011/042548 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 38/00* (2006.01)

(21) International Application Number:
PCT/EP2010/065124

(22) International Filing Date:
8 October 2010 (08.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09290778.1 9 October 2009 (09.10.2009) EP
09290845.8 5 November 2009 (05.11.2009) EP

(71) Applicant *(for all designated States except US)*: **SANOFI-AVENTIS** [FR/FR]; Sanofi-Aventis, 174 avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HUBER, Jochen** [DE/DE]; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BLANCHE, Francis** [FR/FR]; c/o Sanofi-Aventis, Département Brevets, 174, Avenue de France, F-75013 Paris (FR). **DABDOUBI, Tarik** [FR/FR]; c/o Sanofi-Aventis, Département Brevets, 174, Avenue de France, F-75013 Paris (FR). **SOUBRIER, Fabienne** [FR/FR]; c/o Sanofi-Aventis, Département Brevets, 174, Avenue de France, F-75013 Paris (FR).

(74) Agent: **SCHNEIDER, Rudolf**; c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: POLYPEPTIDES FOR BINDING TO THE "RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS" AS WELL AS COMPOSITIONS AND METHODS INVOLVING THE SAME

Fig. 1(A)

Variable regions of light chains with CDRs L1, L2 and L3 indicated:

SEQ ID NO	1	2	4	5
	12345678901234567890123	<------L-1------>	12345678901234	5<-L-2->
1	DIVMTQSQKFMSTSVGDRVSVTC	KASQNVGI------	NVAWYQQKPGQSPKALIY	SASYRYS
2	QAVVTQESALTTSPGETVTLTC	RSSTGAVTTSN---	YANWVQEKPDHLFTGLIG	GTNNRAP
3	QIVLTQSPAIMSASPGEKVTMTC	SASSSVS-------	YMHWYQQKSGTSPKRWIS	DTSKLAS
4	QIVLTQSPAIMSASPGEKVTISC	SASSSVS-------	YMYWYQQKPGSSPKPWIY	RTSNLAS
5	DIVLTQSPASLAVSLGQRATISC	RASKSVGTSDSS--	YMHWYQQKPGQPPKLLIY	LASNLES
6	SDVVLTQTPLSLPVNIGDQASISC	KSTKSLLNSDGFT-	YLDWYLQKPGQSPQLLIY	LVSNRFS
7	NIVMTQSPKSMSMSVGERVTLSC	KASENVG------	TYVSWYQQKPEQSPKLLIY	GASNRYT
8	NIMMTQSPSSLAVSAGEKVTMSC	KSSQSVLYSSNQKNYLA	WYQQKPGQSPKLLIY	WASTRES
9	DIVMTQSQKFMSTSVGDRVSVTC	KASQNVGT------	NVAWYQQKPGQSPKALIY	SASYRYS
10	NIVMTQSPKSMSMSVGERVTLSC	KASENVGT------	YVSWYQQKPEQSPKLLIY	GASNRYT
11	DIVLTQSPASLAVSLGQRATISC	RASKSVSTSGYS--	YMHWYQQKPGQPPKLLIY	LASHLES
12	QAVVTQESALTTSPGETVTLTC	RSSTGAVTTSN---	YANWVQEKPDHLFTGLIG	GTNNRAP
13	SDVVLTQTPLSLPVSIGDQASISC	KSTKSLLNSDGFT-	YLDWYLQKPGQSPQLLIY	LVSNRFS
14	DIVMTQSQKFMSTSVGDRVSVTC	KASQNVGT------	NVAWYQQKPGQSPKALIY	SASYRYS
15	DIVMSQSPSSLAVSVGEKVTMSC	KSSQTLLYSSNQKNYLA	WYQQKPGQSLKLLIY	WASTRES
16	QAVVTQESALTTSPGETVTLTC	RSSTGAVTTSN---	YANWVQEKPDHLFTGLIG	GTNNRAP
17	QAVVTQESALTTSPGETVTLTC	RSSTGAVTTSN---	YANWVQEKPDHLFTGLIR	GTNNRAP
18	DIVLTQSPASLAVSLGQRATISC	RASKSVSISGYS--	YLHWNQQKPGQSPKLLIY	LASNLES
19	DIVMTQSQKFMSTSVGDRVSITC	KASQNVGT------	AVAWYQQKPGQSPKLLIY	SASNRYT
20	DIQMTQSSSYLSVSLGGRVTITC	KASDRINY------	WLAWYQQKPGNAPRLLIS	GATTLET
21	DIVMTQSHKFMSTSVGDRVSITC	KASQDVST------	AVAWYQQKPGQSPKLLIY	SASYRYT
22	QAVVTQESALTTSPGETVTLTC	RSSTGAVTTSN---	YANWVQEKPDHLFTGLIG	GTNNRAP
23	QAVVTQESALTTSPGETVTLTC	RSSTGAVTTSN---	YANWVQEKPDHLFTGLIG	GTNNRSP

(57) **Abstract**: The present invention relates to a polypeptide or polypeptide complex comprising at least the two amino acid sequences arranged to allow for specific binding to the "receptor for advanced glycation endproducts" (RAGE), one or more nucleic acid(s) coding for the polypeptide or polypeptide complex, a cell producing an antibody against RAGE, a pharmaceutical composition comprising at least one polypeptide or nucleic as defined above, optionally for treating a RAGE-related disease or disorder and a method of diagnosing a RAGE-related disease or disorder.

WO 2011/042548 A1